POSTER: Development of Multiplex xMAP Technology-Based Assays for Simultaneous Detection of Soluble Checkpoint Molecules Involved in Anti-Cancer Immune Response

C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Senior Manager, Research and Development, Antibodies and Immunoassays, Thermo Fisher Scientific
    Biography
      Susanne received her PhD at the University of Vienna where she characterized the gene of a major cytoskeletal interlinking protein, plectin, which affects dynamic properties of the cytoskeleton and plays a role in tumor biology. Her postgraduate work focusing on chemotherapy resistance mechanisms in breast cancer cells was carried out at the Ludwig Bolzmann Institute of Clinical Experimental Oncology at the General Hospital in Vienna. Currently Suzanne is a senior scientist in the antibodies and immunoassays group in R&D at Thermo Fisher Scientific. She is a group leader in the multiplex immunoassays development team.

    Abstract:

    To ensure the immune system’s balance between the recognition of non-self and the prevention of autoimmunity, the activity of immune cells needs to be strictly controlled. During the process of cancerogenesis, tumor cells try to resist immune responses and work to suppress the cycle of cancer immunity through multiple mechanisms involving regulatory proteins. These proteins—referred to as immune checkpoints—can affect immunoregulatory pathways by either boosting (co-stimulatory) or restricting (co-inhibitory) the immune response. For the majority of these checkpoint markers, soluble isoforms or shed variants that function as immune adjuvants or decoy receptors, have been identified. To date, cancer therapies that use antibodies targeted to the proteins within these immune checkpoint pathways have proven effective. It is also hypothesized that the measurement of the circulating concentration of the soluble forms of the immune checkpoint proteins could potentially correlate with the clinical efficacy of corresponding checkpoint modulator drugs.

    To test this hypothesis, we developed two comprehensive multiplexing panels (using Luminex® xMAP® technology) that are specifically designed to detect soluble checkpoint molecules involved in T cell and NK cell regulation. The panels allow the simultaneous detection of immune stimulatory and inhibitory factors, allowing a more holistic picture of the molecular players in cancer immunity. Preliminary results using the Invitrogen™ Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex™ Panel 1 (Cat. No. EPX14A-15803-901) and the Invitrogen™ Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex™ Panel 2 (Cat. No. EPX140-15815-901) demonstrate that there are different expression patterns for each that are dependent on both disease state and patient treatment. More in-depth analysis of these soluble biomarkers will hopefully shed more light on the biology of the immune checkpoint pathways and provide a possible tool for monitoring response to therapeutic treatment.

    Learning Objectives:

    • Investigate the advantage of using soluble checkpoint molecules as potential markers for the response to chemotherapy
    • Develop immunoassays for new immune regulating targets

    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    SEP 27, 2019 9:00 AM PDT
    C.E. CREDITS
    SEP 27, 2019 9:00 AM PDT
    DATE: September 27, 2019TIME: 9:00am PT, 12:00pm ET Thienopyrazole derivatives have recently emerged as effective antitumoral agents with kinase inhibitory activity. In this s...
    NOV 21, 2019 9:00 AM PST
    C.E. CREDITS
    NOV 21, 2019 9:00 AM PST
    DATE: November 21, 2019TIME: 9:00am PST, 12:00pm EST Multiple Myeloma is a disease of terminally differentiated plasma cells with the massive production of monoclonal immunoglobu...
    OCT 31, 2019 9:00 AM PDT
    C.E. CREDITS
    OCT 31, 2019 9:00 AM PDT
    DATE: October 31, 2019TIME: 9:00am PDT, 12:00pm EDT INTRODUCTION: A major limitation for the development of 3D engineered tissues is the absence of viable and perfusable...
    Loading Comments...
    Show Resources